These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16186308)

  • 41. Current perspective in insulin therapy in the management of diabetes mellitus.
    Garg MK
    J Indian Med Assoc; 2002 Mar; 100(3):194-5, 202. PubMed ID: 12408284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The peroral therapy of non-insulin-dependent diabetes mellitus].
    Ametov AS; Granovskaia-Tsvetkova AM
    Ter Arkh; 1994; 66(10):17-9. PubMed ID: 7863436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.
    Evans A; Krentz AJ
    Drug Saf; 1999 Jul; 21(1):7-22. PubMed ID: 10433350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects.
    Khedkar A; Iyer H; Anand A; Verma M; Krishnamurthy S; Savale S; Atignal A
    Diabetes Obes Metab; 2010 Aug; 12(8):659-64. PubMed ID: 20590742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy].
    Dakhli S; Lamine S; Lamine F; Trabelsi N; Aouididi F; Zouaoui C; Mami FB; Achour A
    Tunis Med; 2007 Nov; 85(11):945-50. PubMed ID: 19166146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [When oral antidiabetics are no longer enough. Tablets plus basal insulin].
    Meissner T
    MMW Fortschr Med; 2001 Aug; 143(31-32):46. PubMed ID: 11556193
    [No Abstract]   [Full Text] [Related]  

  • 47. [Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].
    Katsuno T; Miyagawa J
    Nihon Rinsho; 2012 May; 70 Suppl 3():693-8. PubMed ID: 22768600
    [No Abstract]   [Full Text] [Related]  

  • 48. Comment on "The broken pen penalty" (Lakshmanadoss et al.).
    Moses AC
    Diabetes Technol Ther; 2010 Nov; 12(11):929-30. PubMed ID: 20879961
    [No Abstract]   [Full Text] [Related]  

  • 49. [Combined insulin-sulfonylurea in type II diabetes mellitus--an update].
    Ravina A; Minuchin O
    Harefuah; 1987 Nov; 113(10):285-7. PubMed ID: 3326798
    [No Abstract]   [Full Text] [Related]  

  • 50. [Inadequate blood glucose control with oral antidiabetic drugs. Early conversion to insulin].
    MMW Fortschr Med; 2002 Jul; 144(27-28):61. PubMed ID: 12198890
    [No Abstract]   [Full Text] [Related]  

  • 51. The market in diabetes.
    Hauber A; Gale EA
    Diabetologia; 2006 Feb; 49(2):247-52. PubMed ID: 16416145
    [No Abstract]   [Full Text] [Related]  

  • 52. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?
    Spoelstra JA; Stolk RP; Heerdink ER; Klungel OH; Erkens JA; Leufkens HG; Grobbee DE
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):121-7. PubMed ID: 12642975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period.
    Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W
    J Am Osteopath Assoc; 1996 Jun; 96(6):346-51. PubMed ID: 8690621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Used of oral antidiabetic agents in pediatric patients - own observations].
    Stańczyk J; Otto-Buczkowska E; Jarosz-Chobot P; Nowowiejska B
    Endokrynol Pol; 2008; 59(5):434-43. PubMed ID: 18979454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current insulin therapy--avoidable errors].
    Mehnert H
    Fortschr Med; 1998 Nov; 116(31):28-30, 32-3. PubMed ID: 9864893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting.
    Hahr AJ; Molitch ME
    Dis Mon; 2010 Mar; 56(3):148-62. PubMed ID: 20189500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Approach to diabetes therapy. 2. Selection and the use of oral antidiabetics. 2) Agents to correct insulin resistance].
    Kashiwagi A; Maegawa H
    Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1530-5. PubMed ID: 11062900
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Inhaled insulin--the breakthrough in the treatment of diabetes?].
    Szymborska-Kajanek A; Wróbel M; Grzeszczak W; Strojek K
    Pol Arch Med Wewn; 2006 Dec; 116(6):1213-9. PubMed ID: 18634534
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.